Cholinesterase inhibitors as Alzheimer's therapeutics

Alzheimer's disease (AD) is one of the most common forms of dementia. AD is a chronic syndrome of the central nervous system that causes a decline in cognitive function and language ability. Cholinergic deficiency is associated with AD, and various cholinesterase inhibitors have been developed for the treatment of AD, including naturally-derived inhibitors, synthetic analogues and hybrids. Currently, the available drugs for AD are predominantly cholinesterase inhibitors. However, the efficacy of these drugs is limited as they may cause adverse side effects and are not able to completely arrest the progression of the disease. Since AD is multifactorial disease, dual and multi-target inhibitors have been developed. The clinical applications and the limitations of the inhibitors used to treat AD are discussed in the present review. Additionally, this review presents the current status and future directions for the development of novel drugs with reduced toxicity and preserved pharmacological activity.

[1]  O. Firuzi,et al.  Multi-target inhibitors against Alzheimer disease derived from 3-hydrazinyl 1,2,4-triazine scaffold containing pendant phenoxy methyl-1,2,3-triazole: Design, synthesis and biological evaluation. , 2019, Bioorganic chemistry.

[2]  B. Larijani,et al.  Design, synthesis and anti-Alzheimer's activity of novel 1,2,3-triazole-chromenone carboxamide derivatives. , 2019, Bioorganic chemistry.

[3]  K. Musílek,et al.  Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy , 2019, Journal of enzyme inhibition and medicinal chemistry.

[4]  J. Lopes,et al.  Design, synthesis, cholinesterase inhibition and molecular modelling study of novel tacrine hybrids with carbohydrate derivatives. , 2018, Bioorganic & medicinal chemistry.

[5]  F. Feng,et al.  Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease. , 2018, European journal of medicinal chemistry.

[6]  E. Uriarte,et al.  Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors. , 2018, European journal of medicinal chemistry.

[7]  E. Sigurdsson,et al.  Tau-targeting therapies for Alzheimer disease , 2018, Nature Reviews Neurology.

[8]  I. Majsterek,et al.  New tacrine–acridine hybrids as promising multifunctional drugs for potential treatment of Alzheimer's disease , 2018, Archiv der Pharmazie.

[9]  Rona R. Ramsay,et al.  A perspective on multi-target drug discovery and design for complex diseases , 2018, Clinical and Translational Medicine.

[10]  Yuqiong Pei,et al.  Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimer’s disease , 2018, Journal of enzyme inhibition and medicinal chemistry.

[11]  Clive,et al.  (−)-Phenserine and Inhibiting Apoptosis: In Pursuit of a Novel Intervention for Alzheimer’s Disease , 2018 .

[12]  Syed Umar Farooq Rizvi,et al.  Cholinesterases inhibition and molecular modeling studies of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones. , 2017, Biochemical and biophysical research communications.

[13]  M. Fraser,et al.  New Gold in Them Thar Hills: Testing a Novel Supply Route for Plant-Derived Galanthamine , 2016, Journal of Alzheimer's disease : JAD.

[14]  Sheung-Tak Cheng.  Cognitive Reserve and the Prevention of Dementia: the Role of Physical and Cognitive Activities , 2016, Current Psychiatry Reports.

[15]  G. Logroscino,et al.  Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease , 2016, BioMed research international.

[16]  N. Greig,et al.  Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms , 2016, PloS one.

[17]  E. Taiwo.  Cashew Nut Shell Oil — A Renewable and Reliable Petrochemical Feedstock , 2015 .

[18]  M. Sabbagh,et al.  Early investigational drugs targeting tau protein for the treatment of Alzheimer’s disease , 2015, Expert opinion on investigational drugs.

[19]  F. Azam,et al.  Ginger components as new leads for the design and development of novel multi-targeted anti-Alzheimer’s drugs: a computational investigation , 2014, Drug design, development and therapy.

[20]  A. Shafiee,et al.  Design, Synthesis, Docking Study and Biological Evaluation of Some Novel Tetrahydrochromeno [3′,4′:5,6]Pyrano[2,3‐b]quinolin‐6(7H)‐one Derivatives Against Acetyl‐ and Butyrylcholinesterase. , 2014 .

[21]  K. Iqbal,et al.  Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease , 2014, Expert opinion on therapeutic targets.

[22]  Sai-Sai Xie,et al.  Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease. , 2013, European journal of medicinal chemistry.

[23]  S. Lovestone,et al.  The Importance of Tau Phosphorylation for Neurodegenerative Diseases , 2013, Front. Neurol..

[24]  A. Cesario,et al.  Multitarget drugs of plants origin acting on Alzheimer's disease. , 2013, Current medicinal chemistry.

[25]  F. Leonetti,et al.  Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. , 2013, Bioorganic & medicinal chemistry.

[26]  D. Choi,et al.  Anti-inflammatory and anti-amyloidogenic effects of a small molecule, 2,4-bis(p-hydroxyphenyl)-2-butenal in Tg2576 Alzheimer’s disease mice model , 2013, Journal of Neuroinflammation.

[27]  Jans H. Alzate-Morales,et al.  A Novel Class of Selective Acetylcholinesterase Inhibitors: Synthesis and Evaluation of (E)-2-(Benzo[d]thiazol-2-yl)-3-heteroarylacrylonitriles , 2012, Molecules.

[28]  Xiaolu Duan,et al.  Tacrine-6-Ferulic Acid, a Novel Multifunctional Dimer, Inhibits Amyloid-β-Mediated Alzheimer's Disease-Associated Pathogenesis In Vitro and In Vivo , 2012, PloS one.

[29]  Hong Liang,et al.  Hybrids of Oxoisoaporphine‐Tacrine Congeners: Novel Acetylcholinesterase and Acetylcholinesterase‐Induced β‐Amyloid Aggregation Inhibitors. , 2012 .

[30]  M. Sabbagh,et al.  New Acetylcholinesterase Inhibitors for Alzheimer's Disease , 2011, International journal of Alzheimer's disease.

[31]  Anna Linusson,et al.  Targeting Acetylcholinesterase: Identification of Chemical Leads by High Throughput Screening, Structure Determination and Molecular Modeling , 2011, PloS one.

[32]  D. Restrepo,et al.  Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome , 2011, Scientific reports.

[33]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[34]  Ding Li,et al.  Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for cholinesterases and amyloid beta aggregation. , 2011, Bioorganic & medicinal chemistry.

[35]  M. Youdim,et al.  A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor. , 2011, International review of neurobiology.

[36]  R. Yan,et al.  Isolation and characterization of endophytic huperzine A-producing fungi from Huperzia serrata , 2011, Journal of Industrial Microbiology & Biotechnology.

[37]  N. Greig,et al.  Phenserine efficacy in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[38]  A. Takashima.  Tau aggregation is a therapeutic target for Alzheimer's disease. , 2010, Current Alzheimer research.

[39]  V. Dohnal,et al.  Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. , 2010, Bioorganic & medicinal chemistry letters.

[40]  R. Choi,et al.  Galangin, a flavonol derived from Rhizoma Alpiniae Officinarum, inhibits acetylcholinesterase activity in vitro. , 2010, Chemico-biological interactions.

[41]  N. Greig,et al.  Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. , 2010, Bioorganic & medicinal chemistry.

[42]  C. Pérez,et al.  Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. , 2010, Journal of medicinal chemistry.

[43]  Zha-Jun Zhan,et al.  Synthesis of physostigmine analogues and evaluation of their anticholinesterase activities. , 2010, Bioorganic & medicinal chemistry letters.

[44]  Silvia Gobbi,et al.  Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238. , 2010, Bioorganic & medicinal chemistry.

[45]  Harald Hampel,et al.  Galantamine for Alzheimer's disease , 2010, Expert opinion on drug metabolism & toxicology.

[46]  Mohamed Ashraf Ali,et al.  Design, synthesis and evaluation of novel 5,6-dimethoxy-1-oxo-2,3-dihydro-1H-2-indenyl-3,4-substituted phenyl methanone analogues. , 2009, Bioorganic & medicinal chemistry letters.

[47]  L. Romeiro,et al.  New potential AChE inhibitor candidates. , 2009, European journal of medicinal chemistry.

[48]  F. J. Luque,et al.  Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. , 2009, Journal of medicinal chemistry.

[49]  U. C. Srivastava,et al.  Acetylcholinesterase :A Versatile Enzyme of Nervous System , 2008 .

[50]  J. Sussman,et al.  Acetylcholinesterase: how is structure related to function? , 2008, Chemico-biological interactions.

[51]  M. Sabbagh,et al.  Donepezil: potential neuroprotective and disease-modifying effects , 2008, Expert opinion on drug metabolism & toxicology.

[52]  F. J. Luque,et al.  Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. , 2008, Journal of medicinal chemistry.

[53]  M. Sabbagh,et al.  Donepezil: potential neuroprotective and disease-modifying effects. , 2008, Expert opinion on drug metabolism & toxicology.

[54]  J. Klein.  Phenserine , 2007, Expert opinion on investigational drugs.

[55]  E. Aguglia,et al.  Rivastigmine in the treatment of Alzheimer’s disease: an update , 2007, Clinical interventions in aging.

[56]  N. Walsh.  Huperzine A for Alzheimer's Disease , 2006 .

[57]  N. Tabet.  Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! , 2006, Age and ageing.

[58]  J. López-arrieta,et al.  Metrifonate for Alzheimer's disease. , 2006, The Cochrane database of systematic reviews.

[59]  J. Sussman,et al.  Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. , 2005, Current opinion in pharmacology.

[60]  N. Greig,et al.  Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. , 2005, Journal of medicinal chemistry.

[61]  U. Thatte.  Phenserine Axonyx. , 2005, Current opinion in investigational drugs.

[62]  A. Mattevi,et al.  Structure and mechanism of monoamine oxidase. , 2004, Current medicinal chemistry.

[63]  K. Tipton,et al.  Monoamine oxidases: certainties and uncertainties. , 2004, Current medicinal chemistry.

[64]  H. Braak,et al.  Neuropathology of Alzheimer’s Disease , 2004 .

[65]  A. Cavalli,et al.  3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. , 2003, Journal of medicinal chemistry.

[66]  J Andrew McCammon,et al.  Role of the catalytic triad and oxyanion hole in acetylcholinesterase catalysis: an ab initio QM/MM study. , 2002, Journal of the American Chemical Society.

[67]  J L Sussman,et al.  X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. , 2002, Biochemistry.

[68]  F. Inglis.  The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. , 2002, International journal of clinical practice. Supplement.

[69]  J L Sussman,et al.  Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. , 2002, Biochemistry.

[70]  V. Tõugu.  Acetylcholinesterase Mechanism of catalysis and inhibition , 2001 .

[71]  N. Greig,et al.  The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics , 2000, Acta neurologica Scandinavica. Supplementum.

[72]  F. J. Luque,et al.  New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. , 2000, Journal of medicinal chemistry.

[73]  H. Ogura,et al.  Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. , 2000, Methods and findings in experimental and clinical pharmacology.

[74]  N. Greig,et al.  Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. , 2000, Biochemical pharmacology.

[75]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[76]  M. Weinstock,et al.  Selectivity of Cholinesterase Inhibition , 1999 .

[77]  J. Sussman,et al.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. , 1999, Structure.

[78]  S. Hagard,et al.  New Horizons , 1998, Promotion & education.

[79]  B. Gulanski,et al.  Metrifonate treatment of the cognitive deficits of Alzheimer's disease , 1998, Neurology.

[80]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[81]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. , 1996, Dementia.

[82]  P. Watkins,et al.  Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. , 1994, JAMA.

[83]  J. Sussman,et al.  Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[84]  M Farlow,et al.  A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. , 1992, JAMA.

[85]  C. Filley.  Diagnosis of Alzheimer's disease. , 1988, Colorado medicine.

[86]  L. Thal,et al.  Oral physostigmine and lecithin improve memory in Alzheimer disease , 1983, Annals of neurology.

[87]  G. Somogyi,et al.  Direct evidence that eseroline possesses morphine-like effects. , 1982, European journal of pharmacology.

[88]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[89]  E. Grazzini,et al.  Reversible inhibition of acetylcholinesterase by eseroline, an opioid agonist structurally related to physostigmine (eserine) and morphine. , 1982, Biochemical pharmacology.

[90]  B. Pettersson,et al.  Levels of metrifonate and dichlorvos in plasma and erythrocytes during treatment of schistosomiasis with Bilarcil. , 2009, Acta pharmacologica et toxicologica.

[91]  M. Swash,et al.  PHYSOSTIGMINE IN ALZHEIMER'S DISEASE , 1979, The Lancet.

[92]  P. Turner.  Plants in the Development of Modern Medicine. , 1973 .

[93]  T. Swain.  Plants in the Development of Modern Medicine , 1972 .

[94]  R. Katz,et al.  The action of tacrine on neuromuscular transmission: a comparison with hexafluorenium. , 1966, British journal of anaesthesia.

[95]  K. Pernov.  [Nivalin and its curative effect on disease of the nervous system]. , 1961, Psychiatrie, Neurologie, und medizinische Psychologie.